Posted by Darlene League on Nov 3rd, 2024
StockNews.com upgraded shares of CorMedix (NASDAQ:CRMD – Free Report) to a sell rating in a report published on Saturday morning.
Other analysts also recently issued reports about the company. Royal Bank of Canada reiterated...
More of this article »